Inify Laboratories AB — Capital/Financing Update 2022

Jun 20, 2022

Inify Laboratories - now listed on Euronext Growth in Oslo under the INIFY ticker

Inify Laboratories - now listed on Euronext Growth in Oslo under the INIFY ticker

Stockholm, June 20[th] 2022

"Today I'm truly thrilled to announce that Inify Laboratories is admitted to

trading on Euronext Growth Oslo, less than 5 months after we became independent.

With solid funding of NOK 150 million, provided through an equity issue towards

supportive long-term shareholders as well as the management and Board of

Directors, we have all prerequisites in place to develop the company and create

a monumental paradigm shift within cancer diagnostics," says Inify Laboratory's

CEO Fredrik Palm.

Inify Laboratories is currently building and establishing an ultra-modern

laboratory that will provide cancer diagnostics within histopathology. Designed

from scratch, it uses a fully digital, standardized and AI-supported workflow to

optimize quality and shorten response times, initially within prostate cancer.

The first laboratory, located at Campus Solna Sweden, is estimated to start

offering services to both public and private healthcare providers before summer

Clinical pathology is currently under high pressure, with heavy workloads and

limited - even declining - resources in many places. Aging populations,

increasing cancer incidence, and more frequent exams and screening programs

further increase the workload. Solving the problem by adding more manpower to

the healthcare providers is simply not possible, as there is an acute lack of

medical professionals within pathology.

"After more than five years of investments in technology development and domain

knowledge, it became clear to us that a laboratory setup, designed from scratch,

is the pathway to making a real difference for patients and medical

professionals in the shortest possible time," says Palm.

Services offered include the whole chain of tissue sample handling, from

logistics and sample preparation, to diagnostic reporting by a pathologist from

either Inify Laboratories or the customer's organization. The diagnosis is

assisted by our own AI software, proven in clinical studies to have world

-leading accuracy. The entire workflow is supported by a tailor-made process

control system. A complete system design ensures seamless integration, thus

supporting an optimal and efficient workflow. Full control over tissue sample

preparation ensures optimal data quality, for further development of powerful AI

software supporting the diagnostic decisions made by the pathologists.

"The concept is scalable in terms of volume, diagnoses and geographical

expansion, which enables global growth potential with business and patient

reach. We offer a unique, attractive workplace for our multidisciplinary team

where we merge technical and medical expertise in the same organization, sharing

our vision to deliver world-leading cancer diagnostics," says Palm.

Inify Laboratory originates from ContextVision, with nearly 40 years of

experience within digital imaging for medical applications, and became

independent through a spin-off in February 2022.

Fredrik Palm, CEO of the Inify Laboratories, will host an online presentation

today, Monday June 20[th] at 13:00 AM.

To attend, please use the following link:

https://attendee.gotowebinar.com/register/2167702991096533003

The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker

INIFY.

For more information, please visit www.inify.com